Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E27.66 EPS (ttm)2.01 Insider Own0.10% Shs Outstand1.67B Perf Week-1.70%
Market Cap92.82B Forward P/E18.65 EPS next Y2.98 Insider Trans-5.81% Shs Float1.67B Perf Month10.64%
Income3.37B PEG1.55 EPS next Q0.66 Inst Own70.10% Short Float0.91% Perf Quarter-1.80%
Sales18.47B P/S5.03 EPS this Y-22.30% Inst Trans-5.40% Short Ratio1.19 Perf Half Y-23.92%
Book/sh9.34 P/B5.95 EPS next Y4.13% ROA10.30% Target Price61.83 Perf Year-17.70%
Cash/sh3.33 P/C16.69 EPS next 5Y17.80% ROE22.70% 52W Range49.03 - 76.59 Perf YTD-17.77%
Dividend1.52 P/FCF- EPS past 5Y-12.20% ROI4.60% 52W High-27.47% Beta0.94
Dividend %2.74% Quick Ratio1.30 Sales past 5Y-3.20% Gross Margin75.70% 52W Low13.30% ATR1.03
Employees25000 Current Ratio1.50 Sales Q/Q21.00% Oper. Margin24.70% RSI (14)50.45 Volatility1.37% 1.71%
OptionableYes Debt/Eq0.44 EPS Q/Q71.10% Profit Margin18.20% Rel Volume0.78 Prev Close55.96
ShortableYes LT Debt/Eq0.37 EarningsOct 27 BMO Payout75.40% Avg Volume12.66M Price55.55
Recom2.50 SMA20-0.55% SMA503.94% SMA200-12.14% Volume9,882,451 Change-0.73%
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Oct-27-14Reiterated MKM Partners Sell $34 → $36
Dec-05-16 07:30PM  Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo (nivolumab) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting Business Wire
03:55PM  Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell
08:38AM  D E Shaw Makes Massive Investments in Apple, Disney, More at Insider Monkey
08:18AM  Assessing Bristol-Myers Stock Valuation (BMY) at Investopedia
05:00AM  Encouraging Survival Observed With Opdivo (nivolumab) Plus Yervoy (ipilimumab) With Longer Follow-up in First-line Advanced Non-small Cell Lung Cancer, in Updated Phase 1b CheckMate -012 Study Business Wire
Dec-03-16 09:43AM  Why Bristol-Myers Squibb Co. Stock Surged in November at Motley Fool
Dec-02-16 03:35PM  $50 Billion Quant Fund Is Making New Bets On These Stocks at Insider Monkey
08:04AM  What Do Analysts Recommend for Gilead Sciences Stock?
Dec-01-16 10:04AM  Major Product Developments for Pfizer
Nov-30-16 10:04AM  Scrutinizing the HCV Market Based on Genotypes
09:54AM  Bristol-Myers Squibb to Take Part at the Citi 2016 Global Healthcare Conference Business Wire
08:00AM  Pharma Needs To Have A Sense Of Urgency at Forbes
06:02AM  Hedge Funds Hate These 5 Huge Stocks -- Should You Sell Them?
Nov-29-16 04:04PM  New Indications May Be Big Opportunity for AbbVies Imbruvica
11:31AM  Is Bristol-Myers Feeling Better? Not Really
10:04AM  How Was Bristol-Myers Squibbs Profitability in 3Q16?
09:30AM  The Zacks Analyst Blog Highlights: Bristol-Myers, Google, Deere, Halliburton and American Airlines
Nov-28-16 11:02AM  3 Top Drug Stocks for Your Retirement Portfolio at Motley Fool
10:04AM  How Did Bristol-Myers Squibbs Virology Segment Perform in 3Q16?
08:05AM  Is Gilead Sciences Stock Oversold?
08:04AM  How Did Bristol-Myers Squibbs Blockbuster Oncology Drug Perform?
Nov-25-16 08:22PM  A Look At Billionaire Julian Robertsons Top Dividend Picks at Insider Monkey
09:40AM  How Does Bristol-Myers Squibbs Valuation Compare to Peers?
08:04AM  Key Investor Insights into Eli Lillys Recent Developments
Nov-24-16 08:04AM  What You Should Know about Eli Lillys Oncology Franchise
Nov-23-16 05:59PM  Final Trade: GM, BMY & more
03:50PM  Bristol-Myers Hodgkin Lymphoma Drug OKed in EU (BMY) at Investopedia
07:38AM  Bristol-Myers' Opdivo Gets EU Approval for Label Expansion
Nov-22-16 06:04PM  These Will Be the Challenges to BMYs Opdivo in the Lung Cancer Space
03:04PM  Understanding Eli Lillys Business Segments by 3Q16 Performance
03:00PM  European Commission Approves Bristol-Myers Squibbs Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin Business Wire
01:12PM  [$$] AstraZeneca given green light to resume cancer drug trials at Financial Times
11:54AM  Where Does Eli Lillys Valuation Stand Next to Peers?
11:04AM  What Do the Analysts Recommend for Bristol-Myers Squibbs Stock?
10:04AM  Inside Bristols Key to Success: Multiple Labels for Opdivo
03:56AM  AstraZeneca cleared to resume enrolment in cancer drug trials Reuters
Nov-21-16 07:01PM  Cramer: Trump Rally is a FANG + FANG Affair
04:35PM  Billionaire Julian Robertson Takes Out Huge SPY Hedge, Grows Bearish on Transportation Stocks at Insider Monkey
11:04AM  Why Is Lung Cancer so Attractive to Bristol, Merck, and Roche?
10:04AM  Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class
08:04AM  Yes, Its a Similar Label for Opdivo and Tecentriq in Lung Cancer
Nov-20-16 12:13PM  Can Bristol-Myers Squibb's Dividend Even Survive? at Motley Fool
Nov-19-16 12:05PM  Better Buy: Celgene Corporation vs. Bristol-Myers Squibb at Motley Fool
Nov-18-16 05:04PM  Understanding Bristols Blockbuster: Opdivos Edge over Keytruda
04:49PM  Bristol Myers Squibb Co. (BMY), Alkermes Plc (ALKS) & More: How Opus Points Bet on Healthcare Sector Paid Off? at Insider Monkey
04:04PM  Opdivos Approval for Head and Neck Cancer: Another Feather in Bristols Cap?
01:40PM  Bristols Revenue Growth Projections in 2016 and 2017
01:39PM  Whats Bristol-Myers Squibb Stock Been Up To?
08:04AM  Pfizers Metabolic, Rare Disease Segments: Hope for the Future?
08:04AM  Novartiss Alcon Continues Its Falling Trend in 3Q16
06:22AM  Pharma Stock Roundup: Data Presented at ACR, Bristol-Myers Inks Immuno-Oncology Deal
Nov-17-16 09:29AM  3 Things Exelixis Must Do to Survive and Thrive in 2017 at Motley Fool
08:17AM  Bristol-Myers, Enterome Ink Immuno-Oncology Collaboration
Nov-16-16 11:17PM  Japan sets 50 pct price cut for Bristol Myers' Opdivo cancer drug Reuters
10:36PM  Japan sets 50 pct price cut for Opdivo cancer drug: Ono Pharma
07:01PM  Roche, Bristol-Myers cut cancer drug prices to win UK approval Reuters
05:13PM  Bristol-Myers Squibb Presents New Data at IASLC 17th World Conference on Lung Cancer Underscoring Progress and Leadership in Broad Lung Development Program Business Wire
04:04PM  Changes in Novartiss Valuation for 3Q16
01:51PM  Most Analysts Rate Novartis a Buy
04:04AM  Bristol-Myers Squibb and Enterome SA Announce Immuno-Oncology Collaboration Focused on Microbiome-derived Biomarkers, Drug Targets and Bioactive Molecules PR Newswire
03:00AM  Bristol-Myers Squibb and Enterome Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules Business Wire
Nov-15-16 10:04AM  AstraZenecas Other Products in 3Q16
08:04AM  Ibrance May Continue to Dominate Breast Cancer Space in 2016
Nov-14-16 06:04PM  Investor Anticipating Bubble Julian Robertson Buys 2 Stocks in 3rd Quarter
05:41PM  AstraZeneca's Symbicort Positive in Pediatric Asthma Study
05:39PM  Bristol-Myers Offers Updates from Opdivo Combination Trials
01:45PM  Bristol-Myers Opdivo Drug Does Well in Study (BMY) at Investopedia
11:55AM  Bristol-Myers Opdivo Nips at Keytruda's Heels (BMY) at Investopedia
09:58AM  Inside the Vanguard Health Care ETF: Bristol-Myers (BMY, VHT) at Investopedia
06:59AM  Bristol-Myers Squibb Showcases Rheumatoid Arthritis and Immunoscience Commitment with Depth of Research at 2016 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting Business Wire
05:50AM  Bristol-Myers Sinks $100M in NASH, Fibrosis (BMY) at Investopedia
Nov-13-16 07:34PM  [$$] Big pharma is failing to do enough for poor countries at Financial Times
Nov-12-16 11:30AM  Opdivo (nivolumab) and Yervoy (ipilimumab) Regimen Shows Promising Efficacy and Safety in Previously Treated Patients With Advanced Form of Bladder Cancer Business Wire
11:15AM  Interim Phase 1/2 Data Show Encouraging Clinical Benefit for Lirilumab in Combination With Opdivo (nivolumab) in Patients With Advanced Platinum Refractory Squamous Cell Carcinoma of the Head and Neck Business Wire
10:40AM  Phase 1/2 Data Combining Urelumab with Opdivo (nivolumab) in Hematologic and Solid Tumors Suggest Increased Antitumor Effect in Patients with Melanoma Business Wire
09:44AM  The Shot Heard Round the World: First Inning of Global Reflation
Nov-11-16 07:19AM  Bristol-Myers Squibb Co. breached its 50 day moving average in a Bullish Manner : BMY-US : November 11, 2016
Nov-10-16 05:00PM  Bristol-Myers Squibbs Opdivo® (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer Business Wire
04:15PM  Bristol-Myers Squibb to Showcase New Data Spanning Rheumatoid Arthritis and Other Autoimmune Diseases at 2016 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting Business Wire
11:19AM  Bristol-Myers Squibb Enters into New Collaboration with Johns Hopkins Focused on Immuno-Oncology Research Business Wire
09:50AM  Bristol-Myers Squibb Company (BMY), Infinity Pharmaceuticals, Inc. (INFI) Team Up On Opdivo Combination Therapy at Insider Monkey
08:15AM  Blog Coverage Bristol-Myers Squibb and Infinity Pharma Collaborate for Clinical Trials to Test Combination Drugs Accesswire
08:14AM  Bristol-Myers' Opdivo succeeds in key stomach cancer study
07:59AM  Bristol-Myers Squibb and Pfizer to Deliver 12 New Eliquis® (apixaban) Presentations at American Heart Association (AHA) Scientific Sessions 2016 Business Wire
07:10AM  Bristol-Myers' Opdivo immunotherapy succeeds in key stomach cancer study
07:01AM  Bristol-Myers' deepens focus on fibrosis with Nitto deal
06:59AM  Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with Nitto Denko for Targeted siRNA Therapy in Advanced Non-alcoholic Steatohepatitis (NASH) and Cirrhosis Due to NASH Business Wire
06:55AM  Opdivo (nivolumab) Demonstrates Overall Survival Benefit in Patients With Unresectable Advanced or Recurrent Gastric Cancer in Phase 3 Study Business Wire
Nov-09-16 08:31AM  Bristol-Myers Squibb to Take Part in Stifel 2016 Health Care Conference Business Wire +5.91%
06:59AM  Bristol-Myers Squibb and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Advanced Solid Tumors PR Newswire
06:59AM  Bristol-Myers Squibb and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with IPI-549 in Advanced Solid Tumors Business Wire
Nov-08-16 04:50PM  3 Stocks Set to Thrive in Pharma's New Price-Conscious World at Motley Fool
04:26PM  Nektar (NKTR) Stock Up on Narrower-than-Expected Q3 Loss
10:04AM  Pfizers 3Q16 Earnings: Profitability and Financial Guidance
Nov-07-16 04:08PM  Exelixis, Inc. Continues Its Solid Launch at Motley Fool
03:59PM  AVEO Pharmaceuticals' (AVEO) Q3 Loss Lower than Expected
09:30AM  Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals
Nov-06-16 08:39AM  The Path To Global Prosperity
Nov-04-16 04:26PM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financia
03:10PM  Fundamentals Remain Strong in the Pharma Sector
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung cancer, renal cell cancer, and melanoma; Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor that is in regulatory review for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,1000187,794Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorNov 01Option Exercise22.14305,9096,772,825998,777Nov 03 05:22 PM
Elicker John ESVP, Public Affairs & IRNov 01Option Exercise0.00494055,505Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorOct 11Option Exercise17.51368,7066,456,042692,868Oct 13 05:00 PM
ANDREOTTI LAMBERTODirectorSep 08Sale56.9710,800615,276323,699Sep 09 04:41 PM
ANDREOTTI LAMBERTODirectorSep 07Sale56.7710,800613,116334,499Sep 09 04:41 PM
Nielsen AnneChief Compliance & Ethics OffSep 03Option Exercise0.001,596029,722Sep 07 04:33 PM
ANDREOTTI LAMBERTODirectorAug 25Sale58.9211,600683,472345,299Aug 25 05:10 PM
ANDREOTTI LAMBERTODirectorAug 24Sale59.4311,600689,359356,899Aug 25 05:10 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,511015,250Aug 03 04:56 PM
ANDREOTTI LAMBERTODirectorJul 08Sale75.0411,600870,461368,499Jul 11 05:12 PM
ANDREOTTI LAMBERTODirectorJul 07Sale73.8611,600856,776380,099Jul 11 05:12 PM
Blin EmmanuelSVP, Chief Strategy OfficerJul 02Option Exercise0.00951012,516Jul 06 05:58 PM
Cuss Francis MEVP & CSOJul 01Option Exercise0.003,6550291,628Jul 06 05:58 PM
Gordon MurdoEVP, Chief Commercial OfficerJul 01Option Exercise0.002,335014,950Jul 06 05:58 PM
ANDREOTTI LAMBERTODirectorJun 29Sale72.799,800713,342392,194Jun 30 05:42 PM
ANDREOTTI LAMBERTODirectorJun 28Sale71.6713,400960,396390,394Jun 30 05:42 PM
Elicker John ESVP, Public Affairs & IRJun 14Sale72.6911,820859,21955,011Jun 16 04:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMay 20Sale70.7930,2012,137,838184,694May 24 05:04 PM
Caldarella Joseph CSVP & ControllerMay 16Sale72.473,519255,00455,238May 17 04:46 PM
Caforio GiovanniChief Executive OfficerMay 05Option Exercise0.008,0400134,549May 09 04:42 PM
Caforio GiovanniChief Executive OfficerMay 03Option Exercise24.7950,4551,250,602145,958May 05 04:31 PM
Caforio GiovanniChief Executive OfficerMay 03Sale71.3134,5942,466,885117,118May 05 04:31 PM
ANDREOTTI LAMBERTODirectorMay 02Option Exercise26.04234,7206,112,787671,514May 04 05:28 PM
Schmukler Louis SPres., Global Mfg. & SupplyMay 02Sale71.9522,2181,598,65221,971May 04 05:28 PM
ANDREOTTI LAMBERTODirectorMay 02Sale71.88234,72016,870,792436,794May 04 05:28 PM
ANDREOTTI LAMBERTODirectorApr 05Sale66.0011,600765,626436,794Apr 06 04:18 PM
ANDREOTTI LAMBERTODirectorApr 04Sale65.7911,600763,216448,394Apr 06 04:18 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554025,260Apr 05 04:59 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0031,624055,059Mar 14 09:44 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0037,1430300,492Mar 14 09:43 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00204,4470574,101Mar 14 09:43 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,860074,177Mar 14 09:43 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0020,460067,864Mar 14 09:44 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,406089,478Mar 14 09:42 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0060,6230132,906Mar 14 09:42 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0057,4840366,730Mar 14 09:42 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0025,435032,069Mar 14 09:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.008,806059,091Mar 14 09:41 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0075,6180247,158Mar 14 09:41 PM
Blin EmmanuelSVP, Head of CommercializationMar 10Option Exercise0.0011,707013,498Mar 14 09:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 10Option Exercise0.0019,309019,608Mar 14 09:41 PM
CAMPBELL LEWIS BDirectorMar 08Option Exercise24.962,50062,4002,500Mar 10 04:36 PM
CAMPBELL LEWIS BDirectorMar 08Sale66.002,500165,0000Mar 10 04:36 PM
Caforio GiovanniChief Executive OfficerMar 06Option Exercise0.002,889079,627Mar 08 04:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 06Option Exercise0.001,28202,611Mar 08 04:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724050,821Mar 08 04:43 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931048,253Mar 08 04:43 PM
LEUNG SANDRAEVP, General CounselMar 06Option Exercise0.005,5740315,121Mar 08 04:41 PM
Elicker John ESVP, Public Affairs & IRMar 06Option Exercise0.001,043053,715Mar 08 04:41 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0100269,043Mar 08 04:42 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,391060,032Mar 08 04:40 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3240169,885Mar 08 04:40 PM
Blin EmmanuelSVP, Head of CommercializationMar 06Option Exercise0.0081901,553Mar 08 04:41 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528024,746Mar 08 04:40 PM
Caldarella Joseph CSVP & ControllerMar 04Sale64.6412,962837,91646,322Mar 07 05:41 PM
Caforio GiovanniChief Executive OfficerFeb 17Option Exercise22.8920,125460,66188,778Feb 19 04:32 PM
LEUNG SANDRAEVP, General CounselFeb 17Option Exercise22.7314,560330,949319,699Feb 19 04:32 PM
Caforio GiovanniChief Executive OfficerFeb 17Sale63.5812,040765,52776,738Feb 19 04:32 PM
LEUNG SANDRAEVP, General CounselFeb 17Sale63.5710,152645,342309,547Feb 19 04:32 PM
ANDREOTTI LAMBERTODirectorFeb 04Option Exercise0.00148,1800445,820Feb 08 04:31 PM
Paliwal Dinesh CDirectorFeb 01Option Exercise0.003,25703,257Feb 03 06:28 PM
ANDREOTTI LAMBERTODirectorJan 05Sale68.1911,600791,028310,424Jan 06 04:40 PM
ANDREOTTI LAMBERTODirectorJan 04Sale66.9311,600776,332322,024Jan 06 04:40 PM
Elicker John ESVP Pub Affairs & Inv RelationJan 03Option Exercise0.00950053,012Jan 05 06:21 PM
ANDREOTTI LAMBERTODirectorDec 15Sale70.0511,600812,580332,852Dec 16 04:39 PM
ANDREOTTI LAMBERTODirectorDec 14Sale68.0011,600788,843344,452Dec 16 04:39 PM